We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tiny Biological Robot Healers Built From Human Cells Could Recognize Bacteria

By LabMedica International staff writers
Posted on 04 Dec 2023

In a pioneering study, researchers have developed microscopic biological robots, termed Anthrobots, from human tracheal cells. More...

These tiny robots, varying in size from the width of a human hair to the tip of a sharpened pencil, are engineered to self-organize and have shown exceptional potential in aiding the growth of neurons across damaged areas in lab environments. This discovery marks an initial step towards their aim of employing patient-specific biobots as innovative tools for regeneration, healing, and disease treatment.

Building on their previous work with Xenobots – multicellular biological robots crafted from frog embryo cells – researchers at Tufts University (Medford, MA, USA) sought to explore whether similar biobots could be constructed from cells of other species. Their earlier Xenobots demonstrated abilities such as navigating spaces, gathering materials, self-healing, and limited self-replication. The new research revealed that biobots can indeed be fashioned from adult human cells without genetic alteration, exhibiting capabilities that surpass those observed with Xenobots. Utilizing human cells offers the advantage of creating biobots from a patient's own cells, reducing the risk of immune reactions or the need for immunosuppressive drugs. These Anthrobots have a limited lifespan, disintegrating after several weeks, allowing for easy reabsorption by the body post-treatment.

To assess the therapeutic potential of Anthrobots, the researchers conducted a laboratory experiment simulating wound healing. Contrary to expectations that genetic modifications might be necessary for the biobots to aid neural growth, the unmodified Anthrobots remarkably stimulated significant regrowth, forming a bridge of neurons as dense as the surrounding healthy cells. The study found that the Anthrobots could not only form new multicellular structures but also traverse a surface covered with human neurons grown in a lab dish to fill in gaps caused by scratching the layer of neuronal cells.

The researchers envision multiple applications for these biobots, including clearing arterial plaque in atherosclerosis, repairing nerve damage in the spinal cord or retina, identifying harmful bacteria or cancer cells, or even delivering medication directly to specific tissues. The potential for Anthrobots to facilitate tissue healing while concurrently administering regenerative drugs opens up exciting prospects in medical science. The team is focused on further developing these biobots to unlock new therapeutic avenues.

“The cellular assemblies we construct in the lab can have capabilities that go beyond what they do in the body,” said Michael Levin, director of the Allen Discovery Center at Tufts. “It is fascinating and completely unexpected that normal patient tracheal cells, without modifying their DNA, can move on their own and encourage neuron growth across a region of damage,” said Levin. “We’re now looking at how the healing mechanism works, and asking what else these constructs can do.”

Related Links:
Tufts University


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Droplet Digital PCR System
QX600 AutoDG
New
PBC Assay
Primary Biliary Cholangitis Assays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.